Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA; Epidemic Intelligence Service, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, USA.
Vaccine. 2021 Oct 8;39(42):6250-6255. doi: 10.1016/j.vaccine.2021.09.020. Epub 2021 Sep 16.
Afghanistan is one of two countries with endemic wild poliovirus type 1 (WPV1). The oral poliovirus vaccine (OPV) is the predominant vaccine used for polio eradication. Although OPV has been administered in routine childhood immunization and during frequent supplementary immunization activities, WPV1 continues to circulate in Afghanistan and case incidence has been increasing since 2017. We estimated the effectiveness of OPV in Afghanistan during 2010-2020.
We conducted a matched case-control analysis using acute flaccid paralysis (AFP) surveillance data from 29,370 children < 15 years with AFP onset between January 1, 2010 and December 31, 2020. We matched children with confirmed WPV1 (cases) with children with non-polio AFP (controls) by age at onset of paralysis (+/- 3 months), date of onset of paralysis (+/- 3 months), and province of residence, and compared their reported OPV vaccination history to estimate the effectiveness of OPV in preventing paralysis by WPV1 using conditional logistic regression. To account for changes in OPV formulations provided over the analysis period, we stratified the analysis based on dates of the global switch from trivalent OPV (tOPV) to bivalent OPV (bOPV) in April 2016.
Between January 1, 2010 and December 31, 2020, there were 329 WPV1 cases in Afghanistan. The per-dose estimated effectiveness of OPV against WPV1 was 19% (95% CI: 15%-22%) and of ≥ 7 doses was 94% (95% CI: 90%-97%). Before the global switch from tOPV to bOPV, the per-dose estimated effectiveness of OPV was 14% (95% CI: 11%-18%) and of ≥ 7 doses was 92% (95% CI: 85%-96%). After the switch, the per-dose estimated effectiveness of OPV against WPV1 was 32% (24%-39%) and of ≥ 7 doses was 96% (95% CI: 90%-99%).
OPV is highly effective in preventing paralysis by WPV1; these results indicate that continued WPV1 transmission in Afghanistan is due to failure to vaccinate, not failure of the vaccine. Although difficult to implement in parts of country, improving the administration of OPV in routine immunization and supplementary immunization activities will be critical for achieving polio eradication in Afghanistan.
阿富汗是两个存在野生 1 型脊髓灰质炎病毒(WPV1)地方性流行的国家之一。口服脊髓灰质炎疫苗(OPV)是用于消灭脊灰的主要疫苗。尽管 OPV 已在常规儿童免疫接种和频繁的补充免疫活动中使用,但 WPV1 仍在阿富汗继续传播,自 2017 年以来病例发病率一直在增加。我们估计了 2010 年至 2020 年期间 OPV 在阿富汗的效果。
我们使用 2010 年 1 月 1 日至 2020 年 12 月 31 日期间 29370 名年龄<15 岁的急性弛缓性麻痹(AFP)监测数据进行了匹配病例对照分析。我们通过发病时的年龄(±3 个月)、发病日期(±3 个月)和居住地省份,将确诊为 WPV1(病例)的儿童与非脊灰 AFP(对照)儿童相匹配,并比较他们报告的 OPV 免疫接种史,以使用条件逻辑回归估计 OPV 预防 WPV1 所致麻痹的效果。为了考虑分析期间 OPV 制剂的变化,我们根据 2016 年 4 月全球从三价 OPV(tOPV)切换为二价 OPV(bOPV)的日期对分析进行分层。
2010 年 1 月 1 日至 2020 年 12 月 31 日期间,阿富汗共发生 329 例 WPV1 病例。OPV 对 WPV1 的单剂估计效果为 19%(95%CI:15%-22%),≥7 剂的估计效果为 94%(95%CI:90%-97%)。在全球从 tOPV 切换到 bOPV 之前,OPV 的单剂估计效果为 14%(95%CI:11%-18%),≥7 剂的估计效果为 92%(95%CI:85%-96%)。切换后,OPV 对 WPV1 的单剂估计效果为 32%(24%-39%),≥7 剂的估计效果为 96%(95%CI:90%-99%)。
OPV 对 WPV1 所致麻痹的预防效果非常高;这些结果表明,阿富汗持续的 WPV1 传播是由于疫苗接种失败,而不是疫苗失效。尽管在该国部分地区难以实施,但改善常规免疫接种和补充免疫活动中 OPV 的管理将是在阿富汗实现消灭脊灰的关键。